NMS Assist for Parkinson's (NCT07038486)
Improve selfmanagement for nonmotor symptoms
- Trial ID
- NCT07038486
- Official Title
- The Impact of a Digital System on the Monitoring and Self-management of Non-motor Symptoms in People With Parkinson's
- Goal
- Improve selfmanagement for nonmotor symptoms
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Newcastle University
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson Disease
- Interventions
- NMS Assist
Summary For Families
The goal is to help people with Parkinson's better monitor and manage non-motor symptoms, like mood, sleep, and autonomic problems, so these often-hidden issues cause less daily disruption. The approach uses a smartphone-based system called NMS Assist that lets users log symptoms, track patterns over time, and receive tailored prompts and summaries to support self-management and communication with caregivers or clinicians. The trial is looking for adults 18 and over with a clinical Parkinson's diagnosis who are ambulant, not living in residential care, fluent in English, and have access to a compatible smartphone. People with significant cognitive impairment or Parkinson's disease dementia, secondary parkinsonism, recent involvement in the system's development, or other serious health issues that would make participation unsafe are excluded, and caregivers of participating patients may also join.
Locations
- Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying NMS Assist. The goal is to help people with Parkinson's better monitor and manage non-motor symptoms, like mood, sleep, and autonomic problems, so these often-hidden issues cause less daily disruption. The approach uses a smartphone-based system called NMS Assist that lets users log symptoms, track patterns over time, and receive tailored prompts and summaries to support self-management and communication with caregivers or clinicians. The trial is looking for adults 18 and over with a clinical Parkinson's diagnosis who are ambulant, not living in residential care, fluent in English, and have access to a compatible smartphone. People with significant cognitive impairment or Parkinson's disease dementia, secondary parkinsonism, recent involvement in the system's development, or other serious health issues that would make participation unsafe are excluded, and caregivers of participating patients may also join.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 1 month.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.